Abstract:Abstract Treatment of glioblastoma (GBM) is challenging due to its heterogeneous nature, invasive potential, and poor response to standard of care treatments. As a result, GBM inevitably recurs and only approximately 7% of patients survive 5 years post-diagnosis. Areas of residual disease represent the source of the recurrent tumor that is fatal for GBM patients. However, targeting the residual disease is not offered as part of the standard of care because these areas are difficult to identify and, to date, they have not been characterized during disease progression. Our laboratory was the first to identify and characterize residual disease in the sub-ventricular zone (SVZ) of the lateral ventricles of GBM patients. Specifically, our work revealed that in 65% of the cases the SVZ contains treatment-resistant cancer stem-like cells (CSCs) that seed the recurrent tumor, thus investigating residual disease in this area may hold the key to developing a valid therapeutic target for many patients. In this study, we are examining the impact of Tumor Treating Fields (TTFields) on treatment-resistant CSCs isolated from the SVZ of GBM patients using molecular techniques, such as single-cell transcriptomics and functional phenotyping analysis. To date, we have isolated and characterized 12 CSCs. These cells are maintained in conditions that preserve the molecular profile of the original patient tumor, thus representing bona fide models to study the impact of TTFields on GBM residual disease. We observed that: (i) CSCs isolated from the SVZ of individual GBM patients show different sensitivity to TTFields, (ii) the anti-proliferative effects of TTFields are maintained at different plating cell densities and among different patients, (iii) as the frequency of TTFields increases from 50 kHz to 200 kHz, CSCs from some patients undergo morphological changes, such as fewer spheres, more round-shaped cells, and fewer connections between cells. Apoptosis is also observed at 150 and 200 kHz. To determine the impact of TTFields on treatment-resistant cancer stem-like cells, we used 100 μM Temozolomide and ionizing radiation (10 Gy) mimicking the standard of care of GBM patients, and (iv) the growth of the treatment-resistant cancer stem-like cells is inhibited by TTFields when this treatment is used at 200 kHz. Ongoing work focuses on single-cell transcriptomics and functional assays of CSCs to elucidate the mechanisms whereby TTFields impact the proliferation of CSCs in the SVZ of GBM patients. In the long run, the results of this work will allow the identification of SVZ-specific targets for the development of novel and more effective treatments for GBM patients. Citation Format: Yamhilette Licon Munoz, Rachel B. Sidebottom, Samantha Varela, Christian A. Bowers, Sara G.M. Piccirillo. Cellular and molecular characterization of cancer stem-like cells isolated from the sub-ventricular zone of glioblastoma patients and treated with Tumor Treating Fields (TTFields) [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr A024.

The EP3–ZNF488 Axis Promotes Self-Renewal of Glioma Stem-like Cells to Induce Resistance to Tumor Treating Fields

Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment

The Transcription Factor ZNF148 Promotes the Malignant Transformation of Dendritic Cells after Cross-Talk with Glioma Stem Cells by Upregulating PTX3

Whole Transcriptome and Proteome Analyses Identify Potential Targets and Mechanisms Underlying Tumor Treating Fields Against Glioblastoma

Upregulation of the <scp>ZNF148</scp>/<scp>PTX3</scp> axis promotes malignant transformation of dendritic cells in glioma stem‐like cells microenvironment

Rbio-08. Investigating The Efficacy And Mechanisms Of Tumor Treating Fields In Radiation-Resistant Glioblastoma Models

Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling

Stem-15. The Impact Of Tumor Treating Fields (Ttfields) On Cancer Stem-Like Cells Isolated From The Sub-Ventricular Zone Of Glioblastoma Patients

Abstract A024: Cellular and molecular characterization of cancer stem-like cells isolated from the sub-ventricular zone of glioblastoma patients and treated with Tumor Treating Fields (TTFields)

IMMU-42. DUAL ACTIVATION OF THE cGAS-STING PATHWAY AND AIM2-INDUCED PYROPTOSIS BY TUMOR-TREATING FIELDS PRODUCES ANTI-TUMOR IMMUNITY IN GLIOBLASTOMA

DDDR-10. MYELOID CELLS COORDINATELY INDUCE GLIOMA CELL-INTRINSIC AND -EXTRINSIC PATHWAYS FOR CHEMORESISTANCE VIA GP130 SIGNALING

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Abstract 2092: Genomic and proteomic analysis of glioblastoma recurrences during TTFields exposure

Abstract 7100: Quantitative proteomics reveal the mechanism of TTFields therapy for glioblastoma

P17.16.B Additional antitumoral activity of TTFields stimulation and Chloride Intracellular Channel 1 inhibition in human glioblastoma primary culture

Human Fibulin-3 Protein Variant Expresses Anti-Cancer Effects in the Malignant Glioma Extracellular Compartment in Intracranial Xenograft Models

Epco-27. Chromatin Remodeling Reprograms The Transcription Network In Glioblastoma

Forkhead Box Protein O3a Promotes Glioma Cell Resistance to Temozolomide by Regulating Matrix Metallopeptidase and Β-Catenin.

Biophysical and Biological Mechanisms of Tumor Treating Fields in Glioblastoma

DNAR-12. COMBINING TUMOUR TREATING FIELDS WITH THERAPEUTIC DNA DAMAGE RESPONSE INHIBITORS TO INCREASE POTENCY IN HIGH-GRADE GLIOBLASTOMAS USING CLINICALLY RELEVANT EX-VIVO GLIOMA STEM CELL MODELS